Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.79 |
| ▸ | MMP2 | P08253 | 13/20 | 0.79 |
| ▸ | MMP9 | P14780 | 13/20 | 0.79 |
| ▸ | EGFR | P00533 | 2/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030602 | 1.00 | MMP1 (0.79) | MMP1MMP2MMP9EGFRHTT | |
| SCHEMBL14983605 | 0.91 | MMP1 (0.76) | MMP1MMP2MMP9EGFRHTT | |
| SCHEMBL9988804 | 0.91 | MMP1 (0.76) | MMP1MMP2MMP9EGFRHTT | |
| SCHEMBL15177196 | 0.88 | EGFR (0.73) | MMP1MMP2MMP9EGFRHTT | |
| SCHEMBL17571910 | 0.87 | MMP1 (0.73) | MMP1MMP2MMP9EGFRHTT | |
| N-P-Tolylcinnamamide SCHEMBL1603280 | 0.86 | MMP1 (1.00) | MMP1MMP2MMP9EGFRHTT | |
| N-P-Tolylcinnamamide SCHEMBL4137542 | 0.86 | MMP1 (1.00) | MMP1MMP2MMP9EGFRHTT | |
| SCHEMBL11028110 | 0.84 | MMP1 (0.90) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL13425358 | 0.84 | MMP1 (0.87) | MMP1MMP2MMP9EGFRHTT | |
| SCHEMBL6755645 | 0.83 | MMP1 (0.71) | MMP1MMP2MMP9EGFRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318981-B2 | Imidate compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100210683-A1 | IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210683-A1 | IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL | CYP1A1, CYC1, C1S | MMP1 2304/4885MMP2 2724/4885MMP9 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.